Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthLucet TMS Coverage & Prior Auth Policy Update | Op…
    Ask Trek AI about this page
    CurrentlucetPolicy 20.5.001

    Transcranial Magnetic Stimulation for Treatment of Major Depression - 2024

    Customize your policy alerts

    Sign up for lucet Policy 20.5.001 alerts

    Get alerted when Policy 20.5.001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Authorization and coverage parameters for use of TMS to treat treatment-resistant major depressive disorder for Lucet members and participating providers during plan year 2024.

    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation for Treatment of Major Depression - 2024
    Policy CodePolicy 20.5.001
    Change TypeNo material change
    Effective DateOct 14, 2024
    Next Review DateNov 23, 2024
    Key ActionSubmit Lucet's TMS Treatment Request Form with clinical history, prior treatment trials, and baseline depression rating scale scores to request prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 weeksStandard acute treatment course

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18-70Allowed age range
    2 trialsMin medication failures
    90867/90868x36/90869Authorization units
    Scale minimumsSeverity thresholds

    Coverage Criteria for Transcranial Magnetic Stimulation (TMS)

    inv-01: Initial Therapy

    Covered when ALL of the following are met

    Initial Authorization

    • Diagnosis and severity: Confirmed diagnosis of severe Major Depressive Disorder WITHOUT psychosis (ICD-9 296.2x/296.3x or ICD-10 F32.x/F33.x) with severity documented by one clinically accepted depression rating scale from Table 1 and meeting listed minimum scores.Refer to rating scale thresholds

      One test chosen and used for entire treatment course.

    • Prior treatment: Either failure of two trials of FDA-approved antidepressants from at least two different classes OR inability to tolerate two trials with documented intolerable side effects OR candidate for ECT where ECT outcome would not be overall superior to TMS.2 trials

      Medication trials must be documented; ECT-preferred scenarios (psychosis, acute suicidality, catatonia) are exclusions for TMS.

    Treatment delivery and monitoring: Standard acute course: one session per day, five days per week for six consecutive weeks, followed by a three-week taper (week 1: 3 sessions; week 2: 2 sessions; week 3: 1 session). Standardized depression rating scales performed pretreatment, every two weeks during the six-week period, and at final visit.6 weeks + 3-week taper; testing every 2 weeks

    If rating scales document lack of meaningful change, physician advisor review may be indicated.

    Provider and setting requirements: Attending physician must be a board-certified psychiatrist with TMS training; clinics/practitioners must be registered with documentation of certification prior to use of benefit.

    Requests submitted on Lucet's TMS Treatment Request Form with required clinical history and baseline rating scale.

    inv-02: Retreatment (Repeat acute treatment)

    Retreatment (Repeat acute treatment) covered when ALL of the following are met

    Retreatment Authorization: Meets all initial treatment requirements AND documents prior response (>=50% improvement on a standard depressive symptom rating scale) AND at least 90 days have elapsed since prior TMS course.>=50% improvement; >=90 days

    If relapse criteria met, repeat acute course of 5 days/week for 6 weeks (30 sessions) plus 3-week taper; frequencies <5 days/week will be reviewed for medical necessity.

    The policy lists specific coverage exclusions. TMS is not covered for members with non-removable metallic objects or implants in the head or neck or with an active neurologic disorder (examples include encephalopathy, dementia, Parkinson’s disease, post-stroke syndromes, increased intracranial pressure or bleeding, cerebral aneurysm, arteriovenous malformations, CSF shunts, or central nervous system implants).

    Coverage is also excluded for requests with evidence of active psychotic symptoms, for Maintenance TMS Treatment, and for treatment of OCD.

    Additionally, the policy excludes specific TMS-related modalities and investigational techniques: Intermittent Theta Burst Stimulation (ITBS), Magnetic Seizure Therapy (MST), and Navigated TMS (nTMS). Finally, TMS requests for psychiatric diagnoses other than Treatment-Resistant Depression (TRD) as defined in this policy are not covered.

    This portion of the document contains no explicit coverage criteria, exclusions, or not medically necessary statements in the Policies, Procedures, or Forms sections.

    Requests for Maintenance TMS are explicitly excluded and considered not medically necessary. The policy further states that retreatment (repeat acute treatment) will only be considered medically necessary when prior response is documented as at least a 50% improvement on a standard depression rating scale and other retreatment criteria are met; if the member did not meet the 50% reduction threshold after the prior course, the retreatment request will be not medically necessary.

    Diagnosis, Procedure Codes, and Rating Scale Thresholds

    Covered diagnosis codesICD-10 | mixedCovered
    ICD-9 296.2xMajor Depressive Disorder, single episode (documented as severe) — listed in policy
    ICD-9 296.3xMajor Depressive Disorder, recurrent (documented as severe) — listed in policy
    ICD-10 F32.xMajor Depressive Disorder, single episode (severe without psychosis) — listed in policy
    ICD-10 F33.xMajor Depressive Disorder, recurrent (severe without psychosis) — listed in policy
    Procedure CPT codes and administration rulesCPTCovered
    90867Interpretation/medical management for TMS — attending physician required to personally perform
    90868TMS delivery by technician — may be administered by certified technician
    90869TMS subsequent management — attending physician required to personally perform
    Depression rating scale minimums
    Beck Depression Inventory (BDI)Minimum score for initial authorization = >29 (21 items)
    Inventory of Depressive Symptomatology, Clinician-rated (IDS-C)Minimum score for initial authorization = >36 (30 items)
    Quick Inventory of Depressive Symptomatology, Self-report (QIDS-SR)Minimum score for initial authorization = >15 (16 items)
    Montgomery–Åsberg Depression Rating Scale (MADRS)Minimum score for initial authorization = >34 (10 items)
    Patient Health Questionnaire (PHQ-9)Minimum score for initial authorization = >19 (9 items)

    Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required via Lucet's TMS Treatment Request Form. Authorized units when TMS is found medically necessary: one (1) unit of CPT 90867, thirty-six (36) units of CPT 90868, and one (1) unit of CPT 90869. Requests for additional units of 90869 must include detailed clinical rationale.

    • Submit Lucet's TMS Treatment Request Form for prior authorization
    • Authorized units if approved: 1 x 90867; 36 x 90868; 1 x 90869
    • Additional 90869 units require detailed clinical rationale
    Prior Authorization

    Prior Authorization

    Prior authorization is required. Ensure the TMS Treatment Request Form and supporting documentation are provided per Lucet's submission processes; timelines will follow Lucet's standard benefit determination timeframes.

    Background on TMS

    Transcranial Magnetic Stimulation (TMS) is a noninvasive neuromodulation technique that delivers electromagnetic pulses to induce cortical neuronal activity. Clinical descriptions distinguish frequency-based approaches, commonly categorized as fast TMS and slow TMS, and note general adverse effects such as local discomfort and rare seizure risk.

    For operational clarity in this policy, "fast" TMS refers to frequencies of 3–20 Hz while "slow" TMS is defined as frequency <1 Hz.

    Definitions and Terminology

    TMS frequency definitions
    Fast TMSFrequencies of 3 to 20 Hz
    Slow TMSFrequency less than 1 Hz
    Definition of Treatment-Resistant Depression (TRD)
    DefinitionTreatment-Resistant Depression (TRD): depression for which TMS is being applied as a non-first-line therapy after prior treatments have failed
    ContextTMS is not a first-line treatment for depression; policy applies to use of TMS in TRD
    Age range relevancePolicy applies to adults; see clinical criteria for specific age limits

    Level of Care and Setting

    TMS Modalities and Techniques

    inv-24: TMS (repetitive TMS)

    TMS modality coverage: Coverage applies to TMS delivered with FDA-approved devices for treatment-resistant major depressive disorder (TRD); certain modalities and uses are not appropriate, including maintenance TMS, treatment for OCD, Intermittent Theta Burst Stimulation (ITBS), Magnetic Seizure Therapy (MST), and Navigated TMS (nTMS).

    Deep TMS for OCD and other non-TRD psychiatric indications are excluded.

    Session Limits and Authorized Units

    TMS treatment sessions and authorized CPT mapping
    Authorized acute sessions30 sessions (5 days/week for 6 weeks)
    Taper scheduleWeek 1 after acute: 3 sessions; Week 2: 2 sessions; Week 3: 1 session (3+2+1 over 3 weeks)
    CPT mapping — initial management90867 — attending physician required to personally perform (1 unit authorized)
    CPT mapping — delivery90868 — TMS delivery by technician (36 units authorized); technician must be certified
    CPT mapping — subsequent management90869 — attending physician required to personally perform (1 unit authorized); requests for additional units require clinical rationale
    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation for Treatment of Major Depression - 2024
    Policy CodePolicy 20.5.001
    Change TypeNo material change
    Effective DateOct 14, 2024
    Next Review DateNov 23, 2024
    Key ActionSubmit Lucet's TMS Treatment Request Form with clinical history, prior treatment trials, and baseline depression rating scale scores to request prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for Transcranial Magnetic Stimulation (TMS)Diagnosis, Procedure Codes, and Rating Scale ThresholdsAuthorization, Documentation, and Provider RequirementsBackground on TMSDefinitions and TerminologyLevel of Care and SettingTMS Modalities and TechniquesSession Limits and Authorized Units
    Denial Risk

    Retreatment Denial Condition

    If a member does not demonstrate a ≥50% improvement on a standard depression rating scale from the prior course, retreatment will not be considered medically necessary.

    Note

    Policies Section — None Provided

    No policies are provided in the Policies section. Providers should not assume additional Lucet policy requirements beyond those stated in this document; contact Lucet if policy detail is required for authorization decisions.

    • POLICIES section: N/A
    Note

    Procedures Section — None Provided

    No procedures are listed in the Procedures section. Ensure all required clinical and administrative procedures (e.g., device-specific protocols, technician certification) are documented on the TMS Treatment Request Form or submitted separately as needed for review.

    • PROCEDURES section: N/A
    Documentation Required

    Forms Section — None Provided

    No forms are provided in the Forms section. The required form for authorization is Lucet's TMS Treatment Request Form; include clinical history, past/current treatment trials, baseline and serial rating scales, and provider certification documentation.

    • FORMS section: N/A
    • Required submission: Lucet's TMS Treatment Request Form with clinical documentation and rating scales
    Step Therapy

    Required Prior Medication Trials

    Required prior medication trials: member must have failed two (2) trials of FDA‑approved antidepressants from at least two different classes, or have documented intolerance to two such trials, unless ECT candidacy or other documented reasons apply.

    • Failure of two trials from at least two different antidepressant classes, OR
    • Documented intolerance to two trials of antidepressants
    Documentation Required

    Required Clinical Documentation and Provider Qualifications

    Clinical documentation required: submit Lucet's TMS Treatment Request Form including clinical history, past and current treatment trials, baseline depression rating scale (choose one from Table 1) and serial rating scales at the required intervals, and provider/clinic certification demonstrating attending psychiatrist board certification and TMS training.

    • Include baseline and serial rating scales (pre-treatment, every two weeks during 6-week course, final visit)
    • Attach documentation of two prior medication trials or documented intolerance
    • Provide attending physician board certification and TMS training/certification
    • Provide clinic/practitioner registration documentation if requested
    Denial Risk

    Not Medically Necessary Conditions

    Not medically necessary / excluded uses include: Maintenance TMS, treatment of OCD, Intermittent Theta Burst Stimulation (ITBS), Magnetic Seizure Therapy (MST), Navigated TMS (nTMS), and TMS for psychiatric diagnoses other than treatment‑resistant depression.

    • Maintenance TMS — not covered
    • OCD treatment — not covered
    • ITBS — not covered
    • MST — not covered
    • nTMS — not covered
    • TMS for DSM-5 psychiatric diagnoses other than TRD — not covered